Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ASBP
stocks logo

ASBP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Valuation Metrics

The current forward P/E ratio for Aspire Biopharma Holdings Inc (ASBP.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Aspire Biopharma Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ASBP News & Events

Events Timeline

(ET)
2025-12-04
09:20:00
Aspire Biopharma Submits New Drug Application, Appoints Interim CEO
select
2025-12-03 (ET)
2025-12-03
06:10:00
Aspire Biopharma Files to Sell 41.5M Shares of Common Stock
select
2025-12-02 (ET)
2025-12-02
09:20:00
Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
Aspire Biopharma Submits Pre-IND Request to FDA for Fast-Acting Sublingual Aspirin with Significant Clinical Benefits
  • FDA Submission Progress: Aspire submitted its Pre-IND meeting request to the FDA on November 3, 2025, for its fast-acting sublingual aspirin, marking a significant milestone that is expected to accelerate the clinical development process toward potential FDA approval.
  • Breakthrough Clinical Data: Clinical trials demonstrated that Aspire's sublingual aspirin inhibits platelet aggregation in under two minutes, acting approximately four to five times faster than chewed aspirin, which holds significant clinical implications for improving treatment outcomes in heart attack patients.
  • Substantial Market Potential: With over 800,000 people in the U.S. experiencing heart attacks annually, Aspire's product could provide a faster and more reliable treatment option, addressing the urgent market demand for effective medical solutions.
  • Optimized Regulatory Pathway: Aspire plans to pursue a 505(b)(2) regulatory pathway, which allows the FDA to consider data from previously approved drugs, potentially reducing development time and costs, thereby enhancing its competitive position in the market.
[object Object]
Preview
2.0
11-18Benzinga
Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Gorilla Technology Group Performance: Gorilla Technology Group Inc. reported a 32% year-over-year revenue increase to $26.5 million for Q3, leading to a 13.7% rise in its share price during pre-market trading.

  • Other Gainers in Pre-Market Trading: Notable stocks that surged include Olema Pharmaceuticals (up 53%), Lobo Technologies (up 40.3%), and Aspire Biopharma (up 30.7%), among others.

  • Losers in Pre-Market Trading: LifeMD Inc. saw a significant drop of 26.2% after disappointing financial results, while Alpha Technology Group and NextPlat Corp also experienced notable declines.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting strong earnings while others faced setbacks.

[object Object]
Preview
4.5
11-16TipRanks
Friday's Major Stock Market Highlights: Morning News Summary!
  • Trading Week Overview: The article discusses the closing of the trading week and highlights key stock market stories from Friday.
  • Top Headlines: A list of the most significant headlines related to the stock market is provided for readers to explore.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aspire Biopharma Holdings Inc (ASBP) stock price today?

The current price of ASBP is 0.0915 USD — it has decreased -1.09 % in the last trading day.

arrow icon

What is Aspire Biopharma Holdings Inc (ASBP)'s business?

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

arrow icon

What is the price predicton of ASBP Stock?

Wall Street analysts forecast ASBP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASBP is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aspire Biopharma Holdings Inc (ASBP)'s revenue for the last quarter?

Aspire Biopharma Holdings Inc revenue for the last quarter amounts to 1.94K USD, decreased % YoY.

arrow icon

What is Aspire Biopharma Holdings Inc (ASBP)'s earnings per share (EPS) for the last quarter?

Aspire Biopharma Holdings Inc. EPS for the last quarter amounts to -0.04 USD, decreased -42.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aspire Biopharma Holdings Inc (ASBP)'s fundamentals?

The market is revising No Change the revenue expectations for ASBP for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -82.12%.
arrow icon

How many employees does Aspire Biopharma Holdings Inc (ASBP). have?

Aspire Biopharma Holdings Inc (ASBP) has 0 emplpoyees as of December 07 2025.

arrow icon

What is Aspire Biopharma Holdings Inc (ASBP) market cap?

Today ASBP has the market capitalization of 9.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free